Comparative effectiveness of neuraminidase inhibitors in patients with influenza: A systematic review and network meta-analysis

Chia Nan University of Pharmacy & Science Institutional Repository > 藥理學院 > 藥學系(所) > 期刊論文 > Item 310902800/34625

jsp.display-item.identifier=請使用永久網址來引用或連結此文件: https://ir.cnu.edu.tw/handle/310902800/34625

標題:	Comparative effectiveness of neuraminidase inhibitors in patients with influenza: A systematic review and network meta-analysis
作者:	Su, Hui-Chen Feng, I-Jung Tang, Hung-Jen Shih, Mei-Fen Hua, Yi-Ming
貢獻者:	Chi Mei Hospital National Sun Yat Sen University Department of Pharmacy, Chia Nan University of Pharmacy & Science
關鍵字:	early oseltamivir treatment double-blind intravenous peramivir oral oseltamivir laninamivir octanoate seasonal influenza inhaled zanamivir virus-infection efficacy safety
日期:	2022
上傳時間:	2023-12-11 14:01:20 (UTC+8)
出版者:	ELSEVIER
摘要:	The aim of this study was to use a network meta-analysis (NWA) to evaluate the relative efficacy and safety of various neuraminidase inhibitors (NAIs) in reducing the duration of influenza symptoms, and thereby, informing the selection of suitable therapeutic regimens for patients with influenza. We conducted a systematic review of randomized controlled trials comparing the clinical effects of four NAIs administered to patients with influenza and placebo. Relevant studies were found in the PubMed and Cochrane databases. Unpublished studies were collected from the ClinicalTrials.gov registry and through hand searching. We carried out NWA to compare the different regimens with each other and across subgroups of age and medical status (high-risk patients). A total of 58 two-arm studies were identified. Five regimens were efficacious in reducing the time to alleviation of influenza symptoms in all populations; this efficacy was comparable. No significant improvements were seen in combination therapy groups. The mean difference in the time to alleviation of symptoms ranged from 12.78 to 19.51 h. According to the summarized mean difference and surface under the cumulative ranking curve (SUCRA), peramivir (SUCRA = 82.6%), zanamivir (SUCRA = 64%), and oseltamivir (SUCRA = 55.1%) were the three top-ranking drugs for treating influenza. Zanamivir and peramivir were the preferred pharmacologic intervention among all investigated interventions based on the calculated value preference of SUCRA. This study is a network meta-analysis to explore the therapeutic effects of NAIs in patients with influenza. Peramivir might be the best choice for reducing the time to alleviation of symptoms.
關聯:	Journal of Infection and Chemotherapy , v.28, Issue 2, pp.158-169
显示于类别:	[藥學系(所)] 期刊論文

文件中的档案:

档案	描述	大小	格式	浏览次数
1-s2.0-S1341321X21003251-main.pdf		4483Kb	Adobe PDF	97	检视/开启
index.html		0Kb	HTML	239	检视/开启

在CNU IR中所有的数据项都受到原著作权保护.

TAIR相关文章

数据加载中.....